Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- AstraZeneca went in big for an artificial antibody-type protein in an up to €2B deal with a Boston-based company
- GSK has injected $140M into its manufacturing expansion in Maryland
- Word on the street is that Sanofi may be trying to acquire Sarepta
- Another M&A rumour that Pfizer may try to acquire BMS has been reinvigorated by Pfizer’s Q1 report
- Shire made a lucrative deal with North Carolina-based Parion to advance ophthalmology candidates
- Qiagen is expanding into China via a partnership with Maccura
- Novartis is adding to its NASH portfolio by availing itself of an exclusive licensing option for emricasan from Conatus
- AstraZeneca has brought its own checkpoint inhibitor to market
- Novartis’ Rydapt has been approved for several more indications, including acute myeloid leukaemia and three more types of systemic mastocytosis
- AlzProtect’s candidate, ASP2006, for Progressive Supranuclear Palsy has been granted Orphan Drug Designation by the FDA
- Switzerland gave Pharmamar Orphan Drug Designation for Aplidin, its multiple myeloma treatment.
- After Abivax’s promising but very early-stage results, researchers in the US also had a breakthrough towards an HIV cure — but they’re using CRISPR.
- Spanish researchers have found that phagocytosis not only clears useless cells but also educates the cannibals as they are imbued with protective properties from their prey.
Images from Brian Lasenby, Eric Axelson, Marco Diaz Segura, Oleksii G / shutterstock.com